You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
AstraZeneca

Last Updated: July 15, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209776

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 209776 describes VABOMERE, which is a drug marketed by Rempex Pharms and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the VABOMERE profile page.

The generic ingredient in VABOMERE is meropenem; vaborbactam. There are thirty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meropenem; vaborbactam profile page.
Summary for 209776
Tradename:VABOMERE
Applicant:Rempex Pharms
Ingredient:meropenem; vaborbactam
Patents:5
Generic Entry Opportunity Date for 209776
Generic Entry Date for 209776*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 209776
Mechanism of Actionbeta Lactamase Inhibitors
Suppliers and Packaging for NDA: 209776
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776 NDA Melinta Therapeutics, Inc. 70842-120 70842-120-06 6 VIAL, SINGLE-DOSE in 1 CARTON (70842-120-06) > 2 g in 1 VIAL, SINGLE-DOSE (70842-120-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrength1GM/VIAL;1GM/VIAL
Approval Date:Aug 29, 2017TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Aug 8, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Aug 8, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
Patent:  Start TrialPatent Expiration:Aug 8, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Medtronic
Dow
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.